The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
Open accessAbstract
The facultative intracellular bacterium Listeria monocytogenes is being developed as a cancer vaccine platform because of its ability to induce potent innate and adaptive immunity. For successful clinical application, it is essential to develop a Listeria platform strain that is safe yet retains the potency of vaccines based on wild-type bacteria. Here, we report the development of a recombinant live-attenuated vaccine platform strain that retains the potency of the fully virulent pathogen, combined with a >1,000-fold reduction in toxicity, as compared with wild-type Listeria. By selectively deleting two virulence factors, ActA (Δ actA) and Internalin B (Δ inlB), the immunopotency of Listeria was maintained and its toxicity was diminished in vivo, largely by blocking the direct internalin B-mediated infection of nonphagocytic cells, such as hepatocytes, and the indirect ActA-mediated infection by cell-to-cell spread from adjacent phagocytic cells. In contrast, infection of phagocytic cells was not affected, leaving intact the ability of Listeria to stimulate innate immunity and to induce antigenspecific cellular responses.Listeria Δ actA/Δ inlB-based vaccines were rapidly cleared from mice after immunization and induced potent and durable effector and memory T-cell responses with no measurable liver toxicity. Therapeutic vaccination of BALB/c mice bearing murine CT26 colon tumor lung metastases or palpable s.c. tumors (>100 mm 3) with recombinant Listeria Δ actA/Δ inlB expressing an endogenous tumor antigen resulted in breaking of self-tolerance and long-term survival. We propose that recombinant Listeria Δ actA/Δ inlB expressing human tumor-associated antigens represents an attractive therapeutic strategy for further development and testing in human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Programmed contraction of CD8+ T cells after infection
Badovinac, V. P., Porter, B. B., & Harty, J. T. (2002) · Nature Immunology · doi:10.1038/ni804 · Cited by 578
Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis
Schaible, U. E., Winau, F., Sieling, P. A., Fischer, K., Collins, H. L., Hagens, K., Modlin, R. L., Brinkmann, V., & Kaufmann, S. H. E. (2003) · Nature Medicine · doi:10.1038/nm906 · Cited by 546
Lecuit, M., Dramsi, S., Gottardi, C., Fedor-Chaiken, M., Gumbiner, B., & Cossart, P. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3956 · Cited by 497
Early Programming of T Cell Populations Responding to Bacterial Infection
Mercado, R., Vijh, S., Allen, S. E., Kerksiek, K., Pilip, I. M., & Pamer, E. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6833 · Cited by 477
Lauer, P., Chow, M. Y. N., Loessner, M. J., Portnoy, D. A., & Calendar, R. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.15.4177-4186.2002 · Cited by 460
Self-citationPrussin, C., & Metcalfe, D. D. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00209-x · Cited by 458
Dual roles of plcA in Listeria monocytogenes pathogenesis
Camilli, A., Tilney, L. G., & Portnoy, D. A. (1993) · Molecular Microbiology · doi:10.1111/j.1365-2958.1993.tb01211.x · Cited by 456
Self-citationMice Lacking the Type I Interferon Receptor Are Resistant to Listeria monocytogenes
Auerbuch, V., Brockstedt, D. G., Meyer-Morse, N., O'Riordan, M., & Portnoy, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040976 · Cited by 450
Self-citation
Cited by
TOX is a critical regulator of tumour-specific T cell differentiation
Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720
Self-citationLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Self-citationBacteria-cancer interactions: bacteria-based cancer therapy
Duong, M. T.-Q., Qin, Y., You, S.-H., & Min, J.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0297-0 · Cited by 519
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
Le, D. T., Brockstedt, D. G., Nir-Paz, R., Hampl, J., Mathur, S., Nemunaitis, J., Sterman, D. H., Hassan, R., Lutz, E., Moyer, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2121 · Cited by 369
Self-citationListeriolysin O: a phagosome-specific lysin
Schnupf, P., & Portnoy, D. A. (2007) · Microbes and Infection · doi:10.1016/j.micinf.2007.05.005 · Cited by 360
Self-citationEngineering living therapeutics with synthetic biology
Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P. F., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 356
Mesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3672 · Cited by 325
Le, D. T., Picozzi, V. J., Ko, A. H., Wainberg, Z. A., Kindler, H., Wang-Gillam, A., Oberstein, P., Morse, M. A., Zeh, H. J., Weekes, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2992 · Cited by 260
Self-citationControlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Vaccine therapy for pancreatic cancer
Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology · doi:10.4161/onci.26662 · Cited by 64
Odegard, J. M., Kelley-Clarke, B., Tareen, S. U., Campbell, D. J., Flynn, P. A., Nicolai, C. J., Slough, M. M., Vin, C. D., McGowan, P. J., Nelson, L. T., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000067 · Cited by 26
Self-citation
Metadata
- Authors
- Brockstedt, D. G., Giedlin, M. A., Leong, M. L., Bahjat, K. S., Gao, Y., Luckett, W., Liu, W., Cook, D. N., Portnoy, D. A., & Dubensky, T. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-09-13
- Volume
- 101
- Issue
- 38
- Pages
- 13832-13837
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1966327293
- Cited by
- 299
- References
- 34
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.